Please assess the completion status of the following clinical trial:

Trial Title: Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, ages 18 or older at screening~2. American Society of Anesthesiologists (ASA) physical status 1, 2, or 3~3. Able to provide informed consent, adhere to the study schedule, and complete all study assessments~4. Primary surgical indication is related to a bunion deformity (i.e., hallux valgus) and subject is scheduled to undergo a distal metaphyseal osteotomy procedure (e.g., Austin procedure as opposed to Lapiplasty, Lapidus bunionectomies or base wedge bunionectomies)~5. Indicated to undergo elective (i.e., not emergency) bunionectomy~6. Body Mass Index (BMI) ≥18 and \<40 kg/m2~Exclusion Criteria:~1. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (e.g., amide-type local anesthetics, opioids, bupivacaine HCl, NSAIDs)~2. Concurrent painful physical condition (e.g. arthritis, fibromyalgia, cancer) that may require analgesic treatment with NSAIDs or opioids in the post dosing period for pain that is not strictly related to the foot surgery and which, in the Investigator's opinion, may confound the post dosing assessments~3. Inadequate sensory function of the foot/ankle as assessed by the Investigator~4. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years~5. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study~6. Previous participation in an EXPAREL study~7. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, could interfere with study assessments or compliance~8. Currently pregnant, nursing, or planning to become pregnant during the study~9. Clinically significant medical disease that, in the opinion of the Investigator, would make participation in a clinical study inappropriate. This includes diabetic neuropathy, coagulation or bleeding disorders, severe peripheral vascular disease, renal insufficiency, hepatic dysfunction or other conditions that would constitute a contraindication to participation in the study~10. Currently on a neuromodulating agent (e.g., gabapentin, pregabalin \[Lyrica\], duloxetine \[Cymbalta\], etc.)~11. Current use of systemic glucocorticoids within 30 days of randomization in this study~12. Use of dexmedetomidine HCl (Precedex®) or clonidine within 3 days of study drug administration~13. Any use of marijuana (including tetrahydrocannabinol (THC) and cannabidiol (CBD)) within 30 days prior to randomization, or planned use during the course of the study~14. Chronic opioid use within 30 days prior to randomization (average ≥30 oral morphine equivalents/day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: EXPAREL 266 mg arm (Type: EXPERIMENTAL): subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline
- Part A: EXPAREL 133 mg arm (Type: EXPERIMENTAL): subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL mixed with 20 mL saline
- Part A: Bupivacaine HCl arm (Type: ACTIVE_COMPARATOR): Subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
- Part B: EXPAREL 133 mg arm OR EXPAREL 266 mg arm (Type: EXPERIMENTAL): Subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline OR 10 mL (133 mg) EXPAREL mixed with 20 mL saline. Dose will be determined following interim analysis of Part A.
- Part B: Bupivacaine HCl arm (Type: ACTIVE_COMPARATOR): subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete